Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
April 17 2024 - 2:00AM
Essential Pharma Announces the Acquisition of Reminyl® (galantamine
hydrobromide) Oral Capsules
Essential Pharma Announces the
Acquisition of Reminyl® (galantamine hydrobromide) Oral
Capsules
Reminyl® is an established CNS brand for the
symptomatic treatment of mild to moderately severe dementia of the
Alzheimer type
The acquisition ensures continued access to this
essential cholinesterase inhibitor for dementia patients in key
markets
Significant addition to Essential Pharma’s
portfolio of specialty central nervous system (CNS) medicines and
further expands the company’s presence globally
Egham, UK – 17 April 2024 –
Essential Pharma, an international specialty pharma group focused
on ensuring that patients have sustainable access to low volume,
clinically differentiated, niche pharmaceutical products across key
therapeutic areas, announces that it has completed the acquisition
of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson
& Johnson company.
Reminyl®, a cholinesterase inhibitor, is an
established central nervous system (CNS) drug indicated for the
treatment of mild to moderately severe dementia of the Alzheimer
type. Under the terms of the acquisition, Essential Pharma has
acquired rights to Reminyl® oral capsules in the EEA, Thailand,
South Korea and all other current markets for that product,
excluding UK and Ireland, Japan and Latin America.
The acquisition of Reminyl® represents further
validation of Essential Pharma’s status as a trusted partner in
ensuring the sustained supply of essential medicines to patients,
healthcare providers and carers. As well as being an important
addition to Essential Pharma’s portfolio of specialty CNS
medicines, the acquisition further expands the Company’s presence
globally, particularly in the APAC region.
Emma Johnson, CEO of Essential Pharma,
commented: “Our acquisition of rights to Reminyl® in these
markets will ensure Alzheimer’s patients and caregivers in those
regions have continued access to this vital medicine. The
acquisition represents a significant and synergistic addition to
our concentrated portfolio of CNS products, further expanding our
global presence and solidifying our position as a leading specialty
pharma group.”
About Essential Pharma
Essential Pharma is an international specialty
pharmaceutical group dedicated to maintaining access to clinically
differentiated, niche, branded medicines across multiple
therapeutic areas. The group has been an important and valued
partner to healthcare providers for over 20 years by giving
underserved patient populations access to medicines that otherwise
might not be available, and addressing clinical unmet needs.
Essential Pharma operates globally in more than 70 countries,
supplying a portfolio of products with a focus on the central
nervous system (CNS), gastroenterology, ophthalmology, and rare
disease. The group’s growth strategy is centred on portfolio
optimisation and a targeted M&A approach to acquire commercial
and late-clinical stage assets in the four therapeutic areas of
focus. It is a trusted partner to multiple pharma companies of all
sizes, with a proven history of integrating assets and managing
complex technology transfers seamlessly while ensuring continuous
and sustainable supply to patients.
Essential Pharma is backed by Gyrus Capital, an
investment firm dedicated to transformational investments in
sectors with long-term sustainable growth, including
healthcare.
For more information, please visit
essentialpharmagroup.com
CONTACTS
Essential Pharma
Email: info@essentialpharmaceuticals.com
ICR Consilium
Tracy Cheung / Chris Welsh / Isabelle Abdou
Tel: +44 (0) 20 3709 5700
Email: Essentialpharma@consilium-comms.com